A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moderate to severe myasthenia gravis
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs CFZ 533 (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors Novartis
- 30 Aug 2017 This trial was completed in Germany (end date: 2017-04-19), according to European Clinical Trials Database.
- 10 Apr 2017 Planned primary completion date changed from 27 Dec 2017 to 31 Jul 2017.
- 12 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Dec 2017.